Edition:
United Kingdom

Bellicum Pharmaceuticals Inc (BLCM.OQ)

BLCM.OQ on NASDAQ Stock Exchange Global Market

9.53USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$9.53
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
159,967
52-wk High
$16.98
52-wk Low
$7.42

Chart for

About

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of... (more)

Overall

Beta: --
Market Cap(Mil.): $377.79
Shares Outstanding(Mil.): 33.23
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Bellicum reports qtrly earnings per share loss‍ $0.71​

* Bellicum Pharmaceuticals Inc qtrly earnings per share loss‍ $0.71​

07 Nov 2017

BRIEF-Bellicum Pharmaceuticals enters a cancer research grant contract with cancer prevention and research institute of Texas

* Bellicum Pharmaceuticals says ‍on Aug. 9, entered a cancer research grant contract with cancer prevention and research institute of Texas

15 Aug 2017

BRIEF-Bellicum Pharmaceuticals qtrly loss per share $0.74

* Bellicum pharmaceuticals reports second quarter 2017 financial results and provides corporate update

08 Aug 2017

BRIEF-Bellicum Pharmaceuticals files for mixed shelf offering of upto $150 mln

* Bellicum Pharmaceuticals Inc files for mixed shelf offering of upto $150 million - sec filing Source text: (http://bit.ly/2tmwwmp) Further company coverage:

28 Jun 2017

BRIEF-Bellicum Pharmaceuticals files prospectus relating to disposition of up to about 5 million shares

* Bellicum Pharmaceuticals files prospectus relating to disposition of up to about 5 million shares of co's common stock held by the selling stockholders

28 Jun 2017

Earnings vs. Estimates